BACKGROUND: Polymorphisms in serotonin re-uptake transporter (SERT or SLC6A4) gene may play role in disturbance in gut function in irritable bowel syndrome (IBS). The aim of this study was to evaluate the association between SLC6A4 polymorphism of SERT-P and serotonin (5-hydroxytryptamine, 5-HT) concentration in IBS as compared with controls. METHODS: 150 patients with IBS (Rome-III criteria) and 252 controls were subjected to SLC6A4 genotyping. 5-HT was measured in the rectal biopsy of patients only. RESULTS: Patients and controls were age and gender-matched. Patients were classified into D-IBS: 79 (52%), C-IBS: 52 (35%) and A-IBS: 19 (13%). SLC6A4 polymorphism differed in IBS and controls [genotypes s/s, 89 (59%), l/s, 44 (29%), and l/l, 17 (12%) vs. s/s, 92 (37%), l/s, 114 (45%), and l/l, 46 (18%), p<0.001]. SLC6A4 s/s genotype was commoner in D-IBS than C-IBS, A-IBS and controls (p<0.001). 5-HT level was higher in D-IBS than A-IBS and C-IBS (154.7±37.1 vs. 112.4±24.6 vs. 104.3±23.7-pmol/mL, p<0.001) and in s/s than l/s and l/l genotypes (151.1±37.3 vs. 105.0±20.9 vs. 100.9±28.0-pmol/mL, p<0.001). IBS with s/s genotype more often had abdominal pain than l/s and l/l [78/89 (87.6%) vs. 19/44 (43%) vs. 5/17 (29%), p<0.001]. 5-HT level was higher among IBS patients with abdominal pain and diarrhea than without (142.9±39.4 vs. 108.4±28.9-pmol/mL, p<0.001) and (140.2±41.3-pmol/mL vs. 121.3±35.0-pmol/mL, p=0.003). CONCLUSION: The frequency of SLC6A4-polymorphism and higher levels of 5-HT were significantly associated with IBS, particularly in patients with diarrhea and abdominal pain, suggesting that SLC6A4 is a potential candidate gene involved in the pathogenesis of IBS.
BACKGROUND: Polymorphisms in serotonin re-uptake transporter (SERT or SLC6A4) gene may play role in disturbance in gut function in irritable bowel syndrome (IBS). The aim of this study was to evaluate the association between SLC6A4 polymorphism of SERT-P and serotonin (5-hydroxytryptamine, 5-HT) concentration in IBS as compared with controls. METHODS: 150 patients with IBS (Rome-III criteria) and 252 controls were subjected to SLC6A4 genotyping. 5-HT was measured in the rectal biopsy of patients only. RESULTS:Patients and controls were age and gender-matched. Patients were classified into D-IBS: 79 (52%), C-IBS: 52 (35%) and A-IBS: 19 (13%). SLC6A4 polymorphism differed in IBS and controls [genotypes s/s, 89 (59%), l/s, 44 (29%), and l/l, 17 (12%) vs. s/s, 92 (37%), l/s, 114 (45%), and l/l, 46 (18%), p<0.001]. SLC6A4 s/s genotype was commoner in D-IBS than C-IBS, A-IBS and controls (p<0.001). 5-HT level was higher in D-IBS than A-IBS and C-IBS (154.7±37.1 vs. 112.4±24.6 vs. 104.3±23.7-pmol/mL, p<0.001) and in s/s than l/s and l/l genotypes (151.1±37.3 vs. 105.0±20.9 vs. 100.9±28.0-pmol/mL, p<0.001). IBS with s/s genotype more often had abdominal pain than l/s and l/l [78/89 (87.6%) vs. 19/44 (43%) vs. 5/17 (29%), p<0.001]. 5-HT level was higher among IBS patients with abdominal pain and diarrhea than without (142.9±39.4 vs. 108.4±28.9-pmol/mL, p<0.001) and (140.2±41.3-pmol/mL vs. 121.3±35.0-pmol/mL, p=0.003). CONCLUSION: The frequency of SLC6A4-polymorphism and higher levels of 5-HT were significantly associated with IBS, particularly in patients with diarrhea and abdominal pain, suggesting that SLC6A4 is a potential candidate gene involved in the pathogenesis of IBS.
Authors: Michael Camilleri; Andrea Shin; Irene Busciglio; Paula Carlson; Andres Acosta; Adil E Bharucha; Duane Burton; Jesse Lamsam; Alan Lueke; Leslie J Donato; Alan R Zinsmeister Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-07-10 Impact factor: 4.052
Authors: Barbara Resnick; N Jennifer Klinedinst; Laura Yerges-Armstrong; Jay Magaziner; Denise Orwig; Marc C Hochberg; Ann L Gruber-Baldini; Gregory E Hicks; Susan G Dorsey Journal: Pain Manag Nurs Date: 2016-06 Impact factor: 1.929
Authors: Sandra Mohr; Nikola Fritz; Christian Hammer; Cristina Martínez; Sabrina Berens; Stefanie Schmitteckert; Verena Wahl; Malin Schmidt; Lesley A Houghton; Miriam Goebel-Stengel; Maria Kabisch; Dorothea Götze; Irina Milovač; Mauro D'Amato; Tenghao Zheng; Ralph Röth; Hubert Mönnikes; Felicitas Engel; Annika Gauss; Jonas Tesarz; Martin Raithel; Viola Andresen; Thomas Frieling; Jutta Keller; Christian Pehl; Christoph Stein-Thöringer; Gerard Clarke; Paul J Kennedy; John F Cryan; Timothy G Dinan; Eamonn M M Quigley; Robin Spiller; Caroll Beltrán; Ana María Madrid; Verónica Torres; Edith Pérez de Arce; Wolfgang Herzog; Emeran A Mayer; Gregory Sayuk; Maria Gazouli; George Karamanolis; Lejla Kapur-Pojskič; Mariona Bustamante; Raquel Rabionet; Xavier Estivil; André Franke; Wolfgang Lieb; Guy Boeckxstaens; Mira M Wouters; Magnus Simrén; Gudrun A Rappold; Maria Vicario; Javier Santos; Rainer Schaefert; Justo Lorenzo-Bermejo; Beate Niesler Journal: J Cell Mol Med Date: 2021-06-24 Impact factor: 5.310